免疫系统
癌症研究
免疫疗法
生物
糖酵解
免疫检查点
肿瘤微环境
重编程
癌症
癌症免疫疗法
信号转导
PD-L1
肿瘤进展
癌细胞
激酶
酪氨酸激酶
下调和上调
细胞生物学
免疫学
化学
逃避(道德)
医学
新陈代谢
细胞
细胞代谢
食管癌
受体酪氨酸激酶
细胞生长
转移
免疫
组蛋白H3
作者
Rixin Chen,Xiao‐Dan Ma,Shui‐Dan Xu,Ao‐Tian Mo,Min‐Hua Deng,Jun Wu,Wei‐Tao Zhuang,Jin‐Ling Duan,Shu‐Huan Xie,Jie Lin,P L Lin,Jiming Tang,Hai‐Yu Zhou,Xiao‐Song Ben,Gui‐Bin Qiao,Dan Xie
标识
DOI:10.1002/advs.202520055
摘要
Metabolic reprogramming is a hallmark of cancer that promotes tumor progression and immune evasion. Here, we identify a NIPAL1-driven metabolic-epigenetic circuit in esophageal squamous cell carcinoma (ESCC) that facilitates tumor growth and suppresses antitumor immunity. Mechanistically, NIPAL1 recruits the tyrosine kinase HCK to phosphorylate LDHA at Y10, enhancing glycolysis and lactate production. Lactate accumulation promotes p300-mediated histone H3K18 lactylation (H3K18la), which transcriptionally activates NIPAL1 expression, establishing a self-sustaining NIPAL1-HCK-p-LDHA-lactate-p300-H3K18la loop. This axis functions independently of NIPAL1's canonical magnesium transporter activity and promotes immune escape by impairing CD8+ T cell function. Pharmacological inhibition of HCK or p300 disrupts this loop and restores antitumor immunity, sensitizing tumors to anti-PD-1 therapy. Clinically, expression of NIPAL1, p-LDHA (Y10), and H3K18la correlates with response to immune checkpoint blockade. Our findings reveal a previously unrecognized NIPAL1-HCK-H3K18la signaling loop that integrates tumor metabolism to immune regulation, offering promising targets to improve immunotherapy efficacy in ESCC.
科研通智能强力驱动
Strongly Powered by AbleSci AI